[Application of novel non-endoscopic device in the screening and early diagnosis of esophageal cancer].

Esophageal cancer (EC) is a dreadful disease with a poor prognosis and poses heavy health burden worldwide. Developing effective methods to identify high-risk individuals is urgently needed for preliminary screening before endoscopy. The novel non-endoscopic device has the potential advantages of low cost, simple operation, and minimal invasiveness. Approximately 90% of participants can swallow the device successfully with high safety profiles, and sufficient esophageal exfoliated cells can be collected for cytological examination and biomarker detection. Cytological examination based on the device combined with trefoil factor 3 (TFF3) protein or DNA methylation examinations could effectively screen Barrett's esophagus-associated dysplasia and early esophageal adenocarcinoma, but large prospective studies are needed to further validate the diagnostic value of this device to improve the quality of evidence. Although the device-based cytological examination in combination with biomarker detection holds promise in the early screening of esophageal squamous dysplasia and early esophageal squamous cell carcinoma, related research is still in its infancy, and there is still a lack of sufficient evidence for population screening in China. Active research into the application of this novel non-endoscopic device in EC screening and early diagnosis is of great significance for optimizing EC screening strategies and improving the early diagnosis of EC.食管癌疾病负担重，严重危害人类生命健康，亟需可浓缩高危人群实现内镜筛查前有效分流的初筛方法。食管新型细胞收集器具有操作简便、成本低且侵入性小的优点，吞咽成功率基本可达90%以上，安全性较高，可收集足量食管黏膜脱落细胞进行细胞学检查及生物标志物检测。采用食管新型细胞收集器进行细胞学检查联合三叶因子3蛋白或DNA甲基化检测可对Barrett食管相关异型增生及早期食管腺癌进行有效初筛，但尚需要开展大样本前瞻性队列研究进一步验证其诊断价值以提高研究证据质量。采用食管新型细胞收集器进行细胞学检查联合生物标志物检测在食管鳞状上皮异型增生及早期食管鳞状细胞癌的初筛中具有一定应用前景，相关研究尚处于起步阶段，尚缺乏用于中国人群筛查的充分证据。积极开展食管新型细胞收集器在食管癌筛查与早期诊断中应用的相关研究，对于优化食管癌筛查策略、提高食管癌早期诊断水平具有重要意义。.